

A3 trihydroxyvitamin D₃, 22-oxa-1 α ,25-dihydroxyvitamin D₃ and 2 β -
(3-hydroxypropyloxy)-1 α ,25-dihydroxyvitamin D₃..

REMARKS


The above claim amendments are made to eliminate improper multi-dependencies under U.S. practice so as to conform with 37 C.F.R. 1.75(c) in order to ensure examination of all claims. The amendments are not "narrowing" amendments. The scope of the claims has not been reduced; no limitations have been added and none are intended.

Applicants respectfully await the results of a first examination on the merits.

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C.
Attorneys for Applicants

By


Sheridan Neimark
Registration No. 20,520

SN:jaa
Telephone No.: (202) 628-5197
Facsimile No.: (202) 737-3528
F:\,Y\UAS\Iida20\PTO\Amd Prelim.doc

Version with Markings to Show Changes Made

4. (Amended) The soft capsule formulation of any ~~one of claims 1 to 3~~claim 1 wherein the ~~base for the said~~ oily solution ~~is~~comprises at least one base material selected from the group consisting of fatty acid glycerides, propylene glycol fatty acid diesters, triacetin, polyethylene glycols and vegetable oils.

6. (Amended) The soft capsule formulation of any ~~one of claims 1 to 5~~claim 1 wherein the active vitamin D₃ is selected from 1 α -hydroxyvitamin D₃, 24-hydroxyvitamin D₃, 25-hydroxyvitamin D₃, 1 α ,24-dihydroxyvitamin D₃, 1 α ,25-dihydroxyvitamin D₃, 1 α ,24,25-trihydroxyvitamin D₃, 22-oxa-1 α ,25-dihydroxyvitamin D₃ and 2 β -(3-hydroxypropyloxy)-1 α ,25-dihydroxyvitamin D₃..